The Cancer Vaccine Clinical Trials Tracker provides an organized, real-time overview of more than 25 active therapeutic and prophylactic cancer vaccine trials across global registries.
It highlights major platforms including mRNA, peptide-based, dendritic cell, and viral vector vaccines designed for melanoma, pancreatic cancer, breast cancer, lung cancer, and other malignancies.
By integrating data from multiple registries and presenting emerging results from Phase 1–3 studies, the tracker outlines the scientific progress that has enabled a modern resurgence in cancer vaccine development, driven by advances in neoantigen identification, mRNA technology, immunologic profiling, and combination immunotherapy strategies.
The dashboard supports researchers, clinicians, patients, investors, and policymakers by offering structured information on trial phases, antigens, biomarkers, endpoints, and geographic distribution.
It also summarizes key breakthroughs, including mRNA-4157/V940 in melanoma and autogene cevumeran in pancreatic cancer, as well as broader regulatory and manufacturing trends that are shaping the field.
While designed as an educational and research resource, the tracker underscores the growing momentum toward personalized cancer immunotherapy and reflects an evolving landscape in which cancer vaccines may soon play a central role in routine oncology practice.